We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen and Allergan claim their biosimilar candidate for Roche’s blockbuster Avastin is clinically equivalent in adult patients with advanced non-small cell lung cancer. Read More
Amgen and Allergan claim their biosimilar candidate is clinically equivalent to Roche’s blockbuster Avastin in adult patients with advanced non-small cell lung cancer. Read More
California biopharmaceutical company Gilead is reporting the first single table regimen combining two drugs proved effective in treating all six genotypes of hepatitis C in four clinical trials. Read More